Scholarlink

<p>Hormone replacement therapy (HRT) has a&#xa0;differentiated impact on tumour risk and requires an individualised benefit–risk assessment. Combined HRT increases breast cancer risk in a&#xa0;dose- and duration-dependent manner, with the choice of preparation and type of progestogen being relevant. After breast cancer, systemic HRT should generally be avoided because of the increased risk of recurrence, particularly in hormone receptor-positive tumours, and is acceptable only in exceptional cases. In contrast, data after early stage endometrial cancer and after serous or mucinous ovarian cancer show no increased risk of recurrence and in some cases, even survival benefits. After colorectal cancer, there is evidence of reduced cancer-specific and overall mortality under HRT. Overall, the absolute excess of cancer cases is usually small and must be weighed against the benefits for vasomotor symptoms, bone health and cardiovascular health.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Menopausale Hormontherapie und Krebs

  • 期刊论文

  • 发表日期：

    2026年7月31日

查看全文
  • Maximilian Klar,
  • Vanadin Seifert-Klauss,
  • Olaf Ortmann

摘要

Hormone replacement therapy (HRT) has a differentiated impact on tumour risk and requires an individualised benefit–risk assessment. Combined HRT increases breast cancer risk in a dose- and duration-dependent manner, with the choice of preparation and type of progestogen being relevant. After breast cancer, systemic HRT should generally be avoided because of the increased risk of recurrence, particularly in hormone receptor-positive tumours, and is acceptable only in exceptional cases. In contrast, data after early stage endometrial cancer and after serous or mucinous ovarian cancer show no increased risk of recurrence and in some cases, even survival benefits. After colorectal cancer, there is evidence of reduced cancer-specific and overall mortality under HRT. Overall, the absolute excess of cancer cases is usually small and must be weighed against the benefits for vasomotor symptoms, bone health and cardiovascular health.